Downloading...
Download

Weight

Can Lilly Redefine Weight Loss Market Leadership?Eli Lilly is rapidly emerging as a dominant force in the burgeoning weight loss drug market, presenting a significant challenge to incumbent leader Novo Nordisk. Lilly has demonstrated remarkable commercial success despite its key therapy, Zepbound (tirzepatide), entering the market well after Novo Nordisk's Wegovy (semaglutide). Zepbound's substantial revenue in 2024 underscores its rapid adoption and strong competitive standing, leading market analysts to project Eli Lilly's obesity drug sales will surpass Novo Nordisk's within the next few years. This swift ascent highlights the impact of a highly effective product in a market with immense unmet demand. The success of Eli Lilly's tirzepatide, the active ingredient in both Zepbound and the diabetes treatment Mounjaro, stems from its dual mechanism targeting GLP-1 and GIP receptors, offering potentially enhanced clinical benefits. The company's market position was further solidified by a recent U.S. federal court ruling that upheld the FDA's decision to remove tirzepatide from the drug shortage list. This legal victory effectively halts compounding pharmacies from producing unauthorized, cheaper versions of Zepbound and Mounjaro, thereby protecting Lilly's market exclusivity and ensuring the integrity of the supply chain for the approved product. Looking ahead, Eli Lilly's pipeline includes the promising oral GLP-1 receptor agonist, orforglipron. Positive Phase 3 trial results indicate its potential as a convenient, non-injectable alternative with comparable efficacy to existing therapies. As a small molecule, orforglipron offers potential advantages in manufacturing scalability and cost, which could significantly expand access globally if approved. Eli Lilly is actively increasing its manufacturing capacity to meet anticipated demand for its incretin therapies, positioning itself to capitalize on the vast and growing global market for weight management solutions.
NYSE:LLYLong
by UDIS_View
🟨 Ned Davis: QQQ/QQEW Bearish StanceHello Traders, Today, we're taking a look at the 63-Day QQQ-QQEW ROC% Spread Indicator. This unique tool provides us with a perspective on the momentum difference between the Invesco QQQ ETF (QQQ) and the First Trust NASDAQ-100 Equal Weighted Index Fund (QQEW) over a 63-day trading period. Credit for this study goes to Ned Davis Research (NDR), who provide quality institutional research. With my recreation, we now can use it for TradingView. USE THE INDICATOR FOR FREE IN YOUR ANALYSIS HERE - Currently, the indicator reading stands at 970, which is above the threshold of 600. According to our backtested data from 2007 to present, this suggests a bearish stance for the next 63 days. Here's a quick breakdown of the backtested results: 👉When the indicator is under -600, the forward returns are 2.0% over 10 days, 3.1% over 21 days, and 9.4% over 63 days. 👉When the indicator is between -600 and 600, the forward returns are 0.6% over 10 days, 1.2% over 21 days, and 3.6% over 63 days. 👉When the indicator is above 600, the forward returns are -0.1% over 10 days, 0.8% over 21 days, and 0.2% over 63 days. 💡As you can see from the chart, the indicator sits at the bottom, and the Relative Strength of QQQ vs QQEW is at the top. The thresholds of 600 and -600 serve as clear turning points, providing valuable insights into potential market shifts. Given the current reading, our analysis suggests a cautious approach for the next 63 days. As always, it's important to use this tool as part of a comprehensive trading strategy and consider other market factors before making any investment decisions. Stay tuned for more updates and happy trading! (Note: This analysis is for educational purposes only and should not be considered as financial advice. Always do your own research before making any investment decisions.)
NASDAQ:QQQShort
by TintinTrading
1
RSLS ReShape Lifesciences Global Weight-Loss Leader | $ TargetOn 6/17/2021 Alliance Global Partners brokerage Boosted the Price Target for RSLS ReShape Lifesciences stock from $12.00 to $18.50! ReShape Lifesciences is America's premier weight-loss solutions company. The FDA-approved Lap-Band® program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. Reshapecare™ virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. (accesswire.com) My price target is 12usd short term.
NASDAQ:RSLSLong
by TopgOptions
7
Playing Volatility: Making a 2020-Averse PortfolioIn this case we normalize the ratio between SPY and FDLO (one of the better-performing min-volatility etfs of the year) to the start of the year. We can clearly see a shift in favour of a min-volatility portfolio as of late. Performing efficient frontier upon FDLO to narrow down our investments, we see that, for maximizing a Sharpe ratio at the current 3-month treasury bond yield, our best options are (in terms of TICKER, WEIGHT): CI,0.20459 LIN,0.14878 CABO,0.01408 CTXS,0.01166 CLX,0.01038 AKAM,0.00986 DPZ,0.00929 DG,0.00923 ADBE,0.00918 INTU,0.00909 and so on. stats: Expected annual return: 22.8% Annual volatility: 10.9% Sharpe Ratio: 1.90 Minimizing volatility as opposed to maximizing Sharpe gives us more tickers (of course, the portfolio was made to be volatility-averse in general... but not COVID-Recession-Averse). For stats of Expected annual return: 14.1% Annual volatility: 8.5% Sharpe Ratio: 1.42, We see: LIN,0.04622 EQC,0.04516 DPZ,0.03391 CLX,0.03318 VZ,0.03257 WMT,0.03243 CHRW,0.02722 CI,0.02714 CABO,0.02352 DOX,0.02221 CHKP,0.02112 And so on...
AMEX:FDLO
by STOCHASTICU
2
Weight Watchers about to gain some weight :DAlright, now that I got the corny title out of the way we can talk about why this stock will do well. This recent drop was huge and the trend is getting close to the 30 week moving average at around $27, it's been trading above the 30 week MA so at this point buying the pullbacks to the 30 week makes sense. The S&P 500 is trending up from the recent break out and that will be the main reason why this would go up. Today volume came in on that big drop and you can see it if you zoom into the 1hr chart, trade this on the weekly just look at the volume for reference on the 1hr. Could it drop a little further? Possibly, but i'd trade this by buying it here and buying more on the way to $27 if it were to continue dropping. The RSI is centered out and the MACD seems to have a way to go so the stock has momentum for what I believe might be 2 big moves to $45 and $65. Let me know what you guys think and feel free to post your ideas!
NASDAQ:WWLong
by eneakume
3 Little Indians Pattern + Divergence With Other Indices + More On a long time frame, we have a “three little Indian” pattern consisting of 3 peaks and 3 rivers. Expect accelerated selling once we return to the 2nd peak high buy institutions From $3000 - $3047.38 (The 2008 Financial Crisis 2.618 Fib Retracement Level) I expect selling pressure to be heavy. We have already fallen out of the most recent ascending wedge 2 days ago, in which we retested the previous support and have proceeded to trade down from there: Divergence on the MACD histogram and the CMF was negative the entire way up. This market traded up on the idea that bad news is good in hopes of a rate cut, completely ignoring the US and macroeconomic slowdown that has begun. That and trade tensions around the globe. Don't get me wrong, I love Trump, but if you think the Chinese will actually give the US a favorable trade deal you're wrong. Here is the current weighting of the top 10 companies in the $SPX (as of July 11, 2019): Rank Company Ticker Weight (%) Price 1 Microsoft Corporation MSFT 4.249644 137.89 2 Apple Inc. AAPL 3.573786 202.46 3 Amazon.com Inc. AMZN 3.356436 2,007.59 4 Facebook Inc. Class A FB 1.959511 200.78 5 Berkshire Hathaway Inc. BRK.B 1.667792 213.36 6 Johnson & Johnson JNJ 1.508331 139.54 7 JPMorgan Chase & Co. JPM 1.474984 114.24 8 Alphabet Inc. Class C GOOG 1.406174 1,142.85 9 Alphabet Inc. Class A GOOGL 1.374452 1,142.67 10 Exxon Mobil Corporation XOM 1.319375 77.43 Total Weight of Top 10: 21.890485% Weight from 12/31/2014 - 3/31/2019: Ticker Company Name 3/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014 MSFT Microsoft Corp. 3.83% 3.73% 2.89% 2.51% 2.48% 2.10% AAPL Apple Inc. 3.60% 3.38% 3.81% 3.21% 3.28% 3.55% AMZN Amazon.com Inc. 3.11% 2.93% 2.05% 1.54% 1.45% 0.65% FB Facebook Inc. 1.68% 1.50% 1.85% 1.40% 1.33% 0.72% BRK.B Berkshire Hathaway 1.65% 1.89% 1.67% 1.61% 1.38% 1.51% JNJ Johnson & Johnson 1.58% 1.65% 1.65% 1.63% 1.59% 1.61% GOOG Alphabet Inc. Class C 1.53% 1.52% 1.39% 1.19% 1.26% 0.85% GOOGL Alphabet Inc. Class A 1.49% 1.49% 1.38% 1.22% 1.27% 0.84% XOM Exxon Mobil Corp. 1.45% 1.37% 1.55% 1.94% 1.81% 2.16% Total: 19.92% 19.46% 18.24% 16.25% 15.85% 13.99% Data gathered from: www.slickcharts.com & siblisresearch.com Top put this into prospective here are some charts: Dow Jones Transports/Dow Jones Industrial Average: NYSE Composite: Russell 2000: WilShire 4500 Index: No one can truly ever time the very top. It can definitely go higher, but please be careful when buying up here. Best of Luck
SP:SPXShort
by BigDGoesHard
4